RxDoctor Payments DataLook up a doctor →

Paul Carnes, MD

Pain Medicine · Raleigh, NCNPI 1417940990

Payments from drug & device makers

$34,279in general payments, 2019–2025

Across 574 payments — averaging $59.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$24K
  • Biotronik NRO, Inc.$2K
  • Medtronic$2K
  • AbbVie$1K
  • Averitas Pharma Inc.$1K
  • Lundbeck LLC$579
  • plus $4K from 46 others

What the payments were for

  • Speaking & faculty fees$150%
  • Travel & lodging$1,59810%
  • Food & beverage$13,60789%
  • Education$730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$34,279 in reported general payments places this provider in the 90th percentile of 182 pain medicine providers in North Carolina.

See all pain medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$536,973
Medicare patients
311
Services billed
11,948

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nucynta ErTapentadol Hcl18$28,517
HorizantGabapentin Enacarbil12$18,270
Buprenorphine31$12,677
Fentanyl41$7,278
ButransBuprenorphine11$5,119
Oxycodone Hcl108$2,411
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen49$1,237
Gabapentin65$926
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen57$901
Tramadol Hcl62$763
Tizanidine Hcl36$758
ValacyclovirValacyclovir Hcl13$722
Methadone Hcl20$676
Acetaminophen-CodeineAcetaminophen With Codeine20$643
Morphine Sulfate12$506

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Nucynta Er$439$28,51718 claims
Arbor Pharmaceuticals, Inc.Horizant$87$18,27012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 182 pain medicine providers in North Carolina.

Other pain medicine in Raleigh

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →